ARTICLE | Clinical News
FDA approves Shire's constipation drug
December 21, 2018 8:44 PM UTC
FDA approved Motegrity prucalopride from Shire plc (LSE:SHP; NASDAQ:SHPG) on Dec. 14 to treat chronic idiopathic constipation (CIC) in adults. The approval came a week ahead of the drug's Dec. 21 PDUFA date...
BCIQ Company Profiles
BCIQ Target Profiles